research use only

Omeprazole Proton Pump inhibitor

Cat.No.S1389

Omeprazole is a proton pump inhibitor that blocks H(+)-K(+)-ATPase, used to treat dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger–Ellison syndrome.
Jump to

Quality Control

Batch: Purity: 99.53%
99.53

Solubility

In vitro
Batch:

DMSO : 69 mg/mL (199.75 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 13 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 345.42 Formula

C17H19N3O3S

Storage (From the date of receipt)
CAS No. 73590-58-6 Download SDF Storage of Stock Solutions

Synonyms N/A SMILES CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
Proton pump
H(+)-K(+)-ATPase
In vitro
Omeprazole potently induces cytochrome P4501A1 mRNA expression in primary human hepatocytes, whereas this effect is not detected in mouse primary hepatocytes. This compound induces transcription of reporter genes via the xenobiotic response element that is recognized by the ligand-activated dioxin receptor in human hepatoma cells. It causes a strong inhibition of basal natural killer (NK) activity in spleen cells (SC) from untreated CD2F1 mice. This chemical causes a rapid, strong effect on various types of cytotoxic lymphocytes ranging from cytotoxicity inhibition to irreversible cell damage. It induces a significant inhibition of cytotoxic activity of all types of effector cells after 30 min incubation. This agent decreases the activation of osteoclasts but increases that of osteoblasts in vitro, in part causing an osteopetrosis-like effect.
In vivo
Omeprazole blocks H(+)-K(+)-ATPase, thus enhances degeneration and macrophage-mediated elimination of parietal cells and also causes an increase in preparietal cell production. This compound temporarily changes the dynamic features of parietal cells in the rabbit to make them die early and grow fast.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/8179010/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-11-07)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06509139 ENROLLING_BY_INVITATION
Helicobacter Pylori Infection; Sex; Bismuth Quadruple Therapy
National Cheng-Kung University Hospital
2024-07-09 PHASE4
NCT07144657 NOT_YET_RECRUITING
MALT Lymphoma of Stomach
National Taiwan University Hospital
2025-09-01 PHASE2
NCT06526455 NOT_YET_RECRUITING
Ulcers, Gastric
Shicai Ye
2024-08-01 PHASE4
NCT06903585 NOT_YET_RECRUITING
Bone Pain Flare; Bone Metastasis
American University of Beirut Medical Center
2025-04 PHASE2
NCT03866668 RECRUITING
Autism; Autism Spectrum Disorder
Stanford University
2019-05-29 PHASE2
NCT06114836 RECRUITING
GERD in Infants
Nationwide Children's Hospital
2024-03-14

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map